-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

Benzinga·10/27/2026 21:08:03
Diffusion vocale
UBS analyst Patrick Wood maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $19 to $14.